8-K Announcements
6Material company update
Dec 31, 2025·SEC
Material company update
Dec 19, 2025·SEC
Material company update
Nov 12, 2025·SEC
Creative Medical Technology Holdings, Inc.(CELZ)Earnings, Financials & Key Ratios
CELZ•NASDAQ
Price updated Jun 19, 2026
AboutCreative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Show more
- Revenue$6K-45.5%
- EBITDA-$6M-6.9%
- Net Income-$6M-9.1%
- EPS (Diluted)-2.52+32.1%
- Gross Margin63.43%+5.7%
- EBITDA Margin-100324.78%-95.9%
- Operating Margin-102380.23%-96.1%
- Net Margin-99916.8%-100.1%
- ROE-86.47%-31.3%
CELZ Key Insights
Creative Medical Technology Holdings, Inc. (CELZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 30.3%
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 48.4% over 5 years
- ✗Shares diluted 61.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CELZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CELZ Price & Volume
Creative Medical Technology Holdings, Inc. (CELZ) stock price & volume — 10-year historical chart
Loading chart...
CELZ Growth Metrics
Creative Medical Technology Holdings, Inc. (CELZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-48.43%
3 Years-59.24%
TTM-78.57%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.67%
Return on Capital
10 Years-61.9%
5 Years-61.9%
3 Years-66.78%
Last Year-88.6%
CELZ Recent Earnings
Creative Medical Technology Holdings, Inc. (CELZ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.38+2.6%
$0.39
Rev
—
—
Q2 2026
Mar 20, 2026Metric
Actual
Est
EPS
$0.80-116.2%
$0.37
Rev
$3,000+0.0%
$3,000
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.48+0.0%
$0.48
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.48+23.8%
$0.63
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.38vs $0.39+2.6% | — |
| Q2 2026 | Mar 20, 2026 | $0.80vs $0.37-116.2% | $3,000vs $3,000+0.0% |
| Q4 2025 | Nov 7, 2025 | $0.48vs $0.48+0.0% | — |
| Q3 2025 | Aug 8, 2025 | $0.48vs $0.63+23.8% | — |
Based on last 12 quarters of dataView full earnings history →
CELZ Peer Comparison
Creative Medical Technology Holdings, Inc. (CELZ) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 1.85B | 14.37 | -17.11 | 191.39% | -5.94% | -17.1% | 0.21 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 RCEL | 99.62M | 4.01 | -2.30 | 11.45% | -62.67% | |||
 VCEL | 2.05B | 40.10 | 125.31 | 16.45% | 7.35% | 6.41% | 0.28 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare CELZ vs Peers
Creative Medical Technology Holdings, Inc. (CELZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELZ Income Statement
Creative Medical Technology Holdings, Inc. (CELZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.8K | 124.4K | 165.5K | 164.5K | 87.75K | 88.6K | 9K | 11K | 6K | 3K |
Revenue Growth % | - | 2491.67% | 33.04% | -0.6% | -46.65% | 0.96% | -89.84% | 22.22% | -45.45% | -78.57% |
Cost of Goods Sold | 8K | 70.38K | 45.5K | 50.6K | 47.95K | 28.49K | 3.6K | 4.4K | 2.19K | 29.85K |
COGS % of Revenue | 166.67% | 56.57% | 27.49% | 30.76% | 54.64% | 32.16% | 40% | 40% | 36.57% | - |
Gross Profit | -3.2K▲ 0% | 54.02K▲ 1788.3% | 120K▲ 122.1% | 113.9K▼ 5.1% | 39.8K▼ 65.1% | 60.11K▲ 51.0% | 5.4K▼ 91.0% | 6.6K▲ 22.2% | 3.81K▼ 42.3% | -26.85K▲ 0% |
Gross Margin % | -66.67% | 43.43% | 72.51% | 69.24% | 45.36% | 67.84% | 60% | 60% | 63.43% | -894.97% |
Gross Profit Growth % | 99.58% | 1788.28% | 122.12% | -5.08% | -65.05% | 51.01% | -91.02% | 22.22% | -42.33% | - |
Operating Expenses | 1.17M | 1.17M | 1.25M | 1.23M | 3.17M | 10.3M | 5.63M | 5.75M | 6.15M | 5.91M |
OpEx % of Revenue | 24470.96% | 939.11% | 755.39% | 746.95% | 3607.53% | 11630.34% | 62505.91% | 52276.92% | 102443.67% | - |
Selling, General & Admin | 898.53K | 1.05M | 1.22M | 1.16M | 2.96M | 3.94M | 3.56M | 3.24M | 3.76M | 3.76M |
SG&A % of Revenue | 18719.29% | 844.44% | 739.11% | 706.35% | 3378.18% | 4450.95% | 39558.99% | 29447.56% | 62724.95% | - |
Research & Development | 260.08K | 96.62K | 0 | 0 | 109.18K | 6.27M | 1.97M | 2.4M | 2.26M | 2.06M |
R&D % of Revenue | 5418.44% | 77.67% | - | - | 124.42% | 7075.46% | 21895.99% | 21825.25% | 37663.27% | - |
Other Operating Expenses | 0 | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 123.33K | 92.75K |
Operating Income | -1.18M▲ 0% | -1.11M▲ 5.4% | -1.13M▼ 1.4% | -1.11M▲ 1.4% | -3.13M▼ 180.4% | -10.24M▼ 227.7% | -5.62M▲ 45.1% | -5.74M▼ 2.2% | -6.14M▼ 6.9% | -5.94M▲ 0% |
Operating Margin % | -24537.63% | -895.68% | -682.88% | -677.71% | -3562.17% | -11562.5% | -62445.91% | -52216.92% | -102380.23% | -198049.63% |
Operating Income Growth % | -53.75% | 5.4% | -1.43% | 1.36% | -180.4% | -227.72% | 45.14% | -2.2% | -6.95% | - |
EBITDA | -1.16M | -1.09M | -1.1M | -1.05M | -3.03M | -10.15M | -5.53M | -5.63M | -6.02M | -5.82M |
EBITDA Margin % | -24204.42% | -878.68% | -666.6% | -637.11% | -3457.24% | -11458.56% | -61394.98% | -51212.81% | -100324.78% | -193996.13% |
EBITDA Growth % | -53.53% | 5.92% | -0.93% | 5% | -189.48% | -234.63% | 45.57% | -1.95% | -6.85% | 5.67% |
D&A (Non-Cash Add-back) | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 123.33K | 121.61K |
EBIT | -1.18M | -12.29M | -6.59M | -35.1M | 23.49M | -10.24M | -5.62M | -5.74M | -6.14M | -5.94M |
Net Interest Income | -377.59K | -1.36M | -1.9M | -1.23M | -4.28M | 100.33K | 333.56K | 250.38K | 147.81K | 180.86K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 100.33K | 333.56K | 250.38K | 147.81K | 180.86K |
Interest Expense | 377.59K | 1.36M | 1.9M | 1.23M | 4.28M | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.48M | -12.54M | -7.35M | -35.21M | 22.34M | 100.33K | 333.56K | 250.38K | 147.81K | 180.86K |
Pretax Income | -2.66M▲ 0% | -13.66M▼ 413.5% | -8.48M▲ 37.9% | -36.33M▼ 328.2% | 19.21M▲ 152.9% | -10.14M▼ 152.8% | -5.29M▲ 47.9% | -5.49M▼ 3.9% | -6M▼ 9.1% | -5.76M▲ 0% |
Pretax Margin % | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -192020.93% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.66M▲ 0% | -13.66M▼ 413.5% | -8.48M▲ 37.9% | -36.33M▼ 328.2% | 19.21M▲ 152.9% | -10.14M▼ 152.8% | -5.29M▲ 47.9% | -5.49M▼ 3.9% | -6M▼ 9.1% | -5.76M▲ 0% |
Net Margin % | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -192066.27% |
Net Income Growth % | -247.11% | -413.54% | 37.87% | -328.18% | 152.89% | -152.8% | 47.88% | -3.91% | -9.13% | 5.39% |
Net Income (Continuing) | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M | -6M | -5.76M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 23.36K |
EPS (Diluted) | -17379.79▲ 0% | -11351.33▲ 34.7% | -5017.67▲ 55.8% | -626.88▲ 87.5% | 56.10▲ 108.9% | -9.28▼ 116.5% | -3.76▲ 59.5% | -3.71▲ 1.3% | -2.52▲ 32.1% | -1.56▲ 0% |
EPS Growth % | -217.62% | 34.69% | 55.8% | 87.51% | 108.95% | -116.54% | 59.48% | 1.33% | 32.08% | 45.67% |
EPS (Basic) | -17379.79 | -11351.33 | -5017.67 | -626.88 | 73.75 | -9.28 | -3.76 | -3.71 | -2.52 | - |
Diluted Shares Outstanding | 153 | 1.2K | 2.07K | 57.95K | 324.86K | 1.09M | 1.41M | 1.48M | 2.38M | 3.7M |
Basic Shares Outstanding | 153 | 1.2K | 2.07K | 57.95K | 260.5K | 1.09M | 1.41M | 1.48M | 2.38M | 3.7M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CELZ Balance Sheet
Creative Medical Technology Holdings, Inc. (CELZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 18.5K | 313.66K | 94.25K | 98.01K | 10.74M | 18.75M | 10.27M | 6.14M | 7.4M | 6.06M |
Cash & Short-Term Investments | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 18.4M | 9.99M | 5.94M | 7.21M | 5.85M |
Cash Only | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 8.32M | 3.47M | 5.94M | 7.21M | 5.72M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 10.08M | 6.52M | 0 | 0 | 125K |
Accounts Receivable | 4.8K | 9.6K | 5.6K | 0 | 2.48K | 0 | 0 | 0 | 52.08K | 105.71K |
Days Sales Outstanding | 365.08 | 28.17 | 12.35 | - | 10.34 | - | - | - | 3.17K | 4.8K |
Inventory | 0 | 0 | 0 | 0 | 10.87K | 10.19K | 6.59K | 2.19K | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | 82.71 | 130.6 | 668.56 | 182 | - | 6.08 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 277.25K | 192.71K | 138.8K | 105.03K |
Total Non-Current Assets | 184.65K | 163.5K | 436.56K | 619.76K | 530.96K | 438.88K | 444.29K | 533.84K | 410.51K | 381.66K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 184.65K | 163.5K | 436.56K | 619.76K | 527.68K | 435.6K | 441.01K | 530.56K | 407.23K | 378.38K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 3.28K | 3.28K | 3.28K | 3.28K | 3.28K | 3.28K |
Total Assets | 203.15K▲ 0% | 477.16K▲ 134.9% | 530.8K▲ 11.2% | 717.77K▲ 35.2% | 11.27M▲ 1469.9% | 19.19M▲ 70.3% | 10.72M▼ 44.2% | 6.67M▼ 37.8% | 7.81M▲ 17.1% | 6.44M▲ 0% |
Asset Turnover | 0.02x | 0.26x | 0.31x | 0.23x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
Asset Growth % | -37.01% | 134.88% | 11.24% | 35.22% | 1469.88% | 70.27% | -44.15% | -37.76% | 17.1% | -31.84% |
Total Current Liabilities | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K | 307.65K |
Accounts Payable | 237.57K | 331.84K | 320.79K | 350.9K | 761.86K | 3.27M | 317.28K | 273.53K | 270.69K | 293.45K |
Days Payables Outstanding | 10.84K | 1.72K | 2.57K | 2.53K | 5.8K | 41.86K | 32.17K | 22.69K | 45.03K | 3.29K |
Short-Term Debt | 501.75K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 375.89K | 10.8K | 371.37K | 639.35K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.31M | 3.24M | 6.48M | 38.58M | 0 | 0 | 0 | 0 | 14.19K | 14.19K |
Current Ratio | 0.01x | 0.07x | 0.01x | 0.00x | 10.22x | 5.64x | 27.65x | 18.73x | 25.97x | 19.69x |
Quick Ratio | 0.01x | 0.07x | 0.01x | 0.00x | 10.21x | 5.64x | 27.64x | 18.72x | 25.97x | 19.69x |
Cash Conversion Cycle | - | - | - | - | -5.71K | - | - | - | - | 1.52K |
Total Non-Current Liabilities | 4.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 915 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K | 307.65K |
Total Debt | 513.46K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | 499.77K | 378K | 973.62K | 690.69K | -10.72M | -8.32M | -3.47M | -5.94M | -7.21M | -5.72M |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.98x |
Interest Coverage | -3.12x | -9.03x | -3.48x | -28.54x | 5.49x | - | - | - | - | - |
Total Equity | -2.24M▲ 0% | -3.99M▼ 78.6% | -8.07M▼ 102.1% | -39.8M▼ 393.1% | 10.22M▲ 125.7% | 15.86M▲ 55.3% | 10.34M▼ 34.8% | 6.34M▼ 38.7% | 7.52M▲ 18.7% | 6.13M▲ 0% |
Equity Growth % | -1317.17% | -78.64% | -102.06% | -393.13% | 125.67% | 55.27% | -34.8% | -38.69% | 18.66% | -30.3% |
Book Value per Share | -14615.51 | -3320.56 | -3903.05 | -686.90 | 31.45 | 14.51 | 7.35 | 4.28 | 3.16 | 1.66 |
Total Shareholders' Equity | -2.24M | -3.99M | -8.07M | -39.8M | 10.22M | 15.86M | 10.34M | 6.34M | 7.51M | 6.11M |
Common Stock | 114.8K | 902.71K | 22.49K | 768.54K | 6.34K | 1.41K | 1.43K | 1.75K | 3.14K | 3.14K |
Retained Earnings | -3.43M | -17.08M | -25.57M | -61.89M | -43.67M | -53.81M | -59.1M | -64.59M | -70.59M | -71.99M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -270.95K | 0 | -10K | -10K |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 23.36K |
CELZ Cash Flow Statement
Creative Medical Technology Holdings, Inc. (CELZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -889.62K | -1.05M | -1.21M | -434.56K | -2.22M | -7.8M | -8.03M | -5.3M | -5.86M | -5.59M |
Operating CF Margin % | -18533.77% | -845.88% | -732.99% | -264.17% | -2524.99% | -8800.19% | -89198.72% | -48193.56% | -97607.42% | - |
Operating CF Growth % | -99.81% | -18.28% | -15.28% | 64.18% | -409.9% | -251.88% | -2.96% | 33.96% | -10.47% | 20.03% |
Net Income | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M | -6M | -5.76M |
Depreciation & Amortization | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 121.74K | 120.02K |
Stock-Based Compensation | 144.16K | 1.88K | 0 | 170.32K | 595.38K | 68.75K | 36.65K | 36.65K | 3.48K | 0 |
Deferred Taxes | 347.56K | 11.19M | 0 | 33.98M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.1M | 1.26M | 7.18M | 979.96K | -22.36M | 0 | -34.09K | 0 | 0 | -19.92K |
Working Capital Changes | 158.06K | 129.43K | 62.2K | 692.79K | 249.47K | 2.19M | -2.84M | 45.09K | 13.34K | 73.67K |
Change in Receivables | -4.8K | -4.8K | 4K | 5.6K | -2.48K | 2.48K | 0 | 0 | 0 | 0 |
Change in Inventory | 2.41M | 4.2M | 0 | 0 | -10.87K | 672 | 3.6K | 4.4K | 2.19K | 994 |
Change in Payables | 171.18K | 94.76K | -11.05K | 30.11K | 410.96K | 2.51M | -2.95M | -43.85K | -2.84K | 37.55K |
Cash from Investing | 0 | 0 | 0 | -250K | 0 | -10.08M | 3.45M | 6.32M | -50.5K | -212.14K |
Capital Expenditures | 0 | 0 | 0 | -250K | 0 | 0 | -100K | -200K | 0 | 0 |
CapEx % of Revenue | - | - | 0% | 151.98% | - | - | 1111.11% | 1818.18% | 0.08% | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.36K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -50.5K | -100.5K |
Cash from Financing | 681.45K | 1.34M | 997.68K | 693.92K | 12.84M | 15.47M | -270.95K | 1.45M | 7.17M | 3.82M |
Debt Issued (Net) | 573.25K | 1.34M | 997.68K | 693.92K | -1.63M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 15.02M | 15.47M | -270.95K | 1.45M | 7.16M | 3.81M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -270.95K | -174.96K | -10K | 0 |
Other Financing | 108.2K | 0 | 0 | 0 | -548.31K | 457 | 0 | 0 | 10K | 10K |
Net Change in Cash | -208.17K▲ 0% | 290.36K▲ 239.5% | -215.41K▼ 174.2% | 9.36K▲ 104.3% | 10.63M▲ 113375.6% | -2.4M▼ 122.6% | -4.85M▼ 102.0% | 2.47M▲ 151.0% | 1.27M▼ 48.7% | -1.98M▲ 0% |
Free Cash Flow | -889.62K▲ 0% | -1.05M▼ 18.3% | -1.21M▼ 15.3% | -684.56K▲ 43.6% | -2.22M▼ 223.7% | -7.8M▼ 251.9% | -8.13M▼ 4.2% | -5.3M▲ 34.8% | -5.86M▼ 10.5% | -5.59M▲ 0% |
FCF Margin % | -18533.77% | -845.88% | -732.98% | -416.14% | -2524.99% | -8800.19% | -90309.83% | -48193.56% | -97607.42% | -186274.1% |
FCF Growth % | -95.42% | -18.28% | -15.28% | 43.57% | -223.68% | -251.88% | -4.24% | 34.78% | -10.47% | 6.8% |
FCF per Share | -5814.52 | -874.70 | -586.60 | -11.81 | -6.82 | -7.13 | -5.77 | -3.58 | -2.46 | -1.51 |
FCF Conversion (FCF/Net Income) | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x | 0.98x | 0.97x |
Interest Paid | 0 | 0 | 0 | 0 | 9.19K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CELZ Key Ratios
Creative Medical Technology Holdings, Inc. (CELZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | 188.02% | -77.78% | -40.34% | -65.85% | -86.47% | -88.38% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -218.34% | -58.46% | -118.38% | -1284% | -1437.38% |
Gross Margin | -66.67% | 43.43% | 72.51% | 69.24% | 45.36% | 67.84% | 60% | 60% | 63.43% | -894.97% |
Net Margin | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -192066.27% |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Interest Coverage | -3.12x | -9.03x | -3.48x | -28.54x | 5.49x | - | - | - | - | - |
FCF Conversion | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x | 0.98x | 0.97x |
Revenue Growth | - | 2491.67% | 33.04% | -0.6% | -46.65% | 0.96% | -89.84% | 22.22% | -45.45% | -78.57% |
Related:CELZ Dividend History·CELZ Revenue History·CELZ Price History·CELZ P/E History·CELZ Financial Ratios·CELZ Institutional Holders
CELZ SEC Filings & Documents
Creative Medical Technology Holdings, Inc. (CELZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
CELZ Frequently Asked Questions
Creative Medical Technology Holdings, Inc. (CELZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Creative Medical Technology Holdings, Inc. (CELZ) reported $0.0M in revenue for fiscal year 2025.
Creative Medical Technology Holdings, Inc. (CELZ) saw revenue decline by 45.5% over the past year.
Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $5.8M for fiscal year 2025.
Dividend & Returns
Creative Medical Technology Holdings, Inc. (CELZ) has a return on equity (ROE) of -86.5%. Negative ROE indicates the company is unprofitable.
Creative Medical Technology Holdings, Inc. (CELZ) had negative free cash flow of $5.6M in fiscal year 2025, likely due to heavy capital investments.